ENDPOINTS

Sanofi stops all but the most urgent trips to China; Flurry of orphan drug designations arrive

6 years ago

News Briefing

British Heart Foundation unveils shortlist for £30M research award; Onconova scraps China partnership

6 years ago

News Briefing

AstraZeneca scores orphan status for PD-L1/CTLA-4 combo; EMA OKs Novartis' MS drug Mayzent

6 years ago

News Briefing

Intercept's NASH decision date is deferred; EMA investigates safety of LEO Pharma gel

6 years ago

News Briefing

FDA grants priority review for Rubraca; Arpeggio snags $3.2M in seed financing

6 years ago

News Briefing

Xencor, Verastem ink new deals; Scynexis' lead drug scores again

6 years ago

News Briefing

Phathom Pharmaceuticals snatches up another Celgene exec; True North bets $74M for a stake in Biocon Biologics

6 years ago

News Briefing

Here are the 52 new drugs approved by the FDA in 2019. Who won? Who lost? And who just survived to 2020?

6 years ago

Special

Pharma

Biogen hands over $45M cash to license a tau project for Alzheimer's; Novartis launches a lottery for free dose of ...

6 years ago

News Briefing

Charles River Labs forks over $380M cash for cell therapy player; Axsome soars on PhIII depression readout

6 years ago

News Briefing

Evenity finally wins EU approval; US-China biologics CDMO raises $60M

6 years ago

News Briefing

Stefan Fraenkel takes over as chief of Inceptua Group; Christi Shaw has a plan to make Yescarta safer

6 years ago

News Briefing

Early-stage cancer biotech nails $85M C round; Flemming Ornskov's Galderma scores 'breakthrough' status

6 years ago

News Briefing

Antibiotic developer scores $50M from biotech billionaire; Biohaven's Alzheimer's drug passes futility test

6 years ago

News Briefing

AstraZeneca, Merck score China OK for Lynparza; Regeneron spotlights mid-stage data for rare disease drug

6 years ago

News Briefing

Japanese biotech pitching iPSC-derived med for the heart gains $26M; Andreessen Horowitz leads $4.1M seed funding for ...

6 years ago

News Briefing

Abbott Laboratories CEO Miles White passes baton down to successor; Lonza CEO Marc Funk hits the exit

6 years ago

Peer Review

Seattle and Daiichi Sankyo at each other's throats; UC Berkeley, UCSF and the University of Washington launch Weill ...

6 years ago

News Briefing

Teva spinout raises $85M in IPO; Novartis beefs up generics unit with $440M deal

6 years ago

News Briefing

Special report: Twenty extraordinary women in biopharma R&D who worked their way to the top

6 years ago

People

Special

AncestryDNA chief takes on liquid biopsy challenge; Thomas Lynch chairs former colleague's cancer startup

6 years ago

Peer Review

Gilead's ex-investor relations chief takes CFO job at Sangamo; Former GE Healthcare exec takes the helm at Vectura ...

6 years ago

Peer Review

Christopher Haqq joins Elicio to hunt father's RAS cancer; Kronos expands top team with Gilead, Baylor vets

6 years ago

Peer Review

about the author

author articles

Sanofi stops all but the most urgent trips to China; Flurry of orphan drug designations arrive

British Heart Foundation unveils shortlist for £30M research award; Onconova scraps China partnership

AstraZeneca scores orphan status for PD-L1/CTLA-4 combo; EMA OKs Novartis' MS drug Mayzent

Intercept's NASH decision date is deferred; EMA investigates safety of LEO Pharma gel

FDA grants priority review for Rubraca; Arpeggio snags $3.2M in seed financing

Xencor, Verastem ink new deals; Scynexis' lead drug scores again

Phathom Pharmaceuticals snatches up another Celgene exec; True North bets $74M for a stake in Biocon Biologics

Here are the 52 new drugs approved by the FDA in 2019. Who won? Who lost? And who just survived to 2020?

Biogen hands over $45M cash to license a tau project for Alzheimer's; Novartis launches a lottery for free dose of ...

Charles River Labs forks over $380M cash for cell therapy player; Axsome soars on PhIII depression readout

More questions than answers for biopharma after UK election; Intercept gets FDA advisory date, and a PDUFA delay

Evenity finally wins EU approval; US-China biologics CDMO raises $60M

Stefan Fraenkel takes over as chief of Inceptua Group; Christi Shaw has a plan to make Yescarta safer

Early-stage cancer biotech nails $85M C round; Flemming Ornskov's Galderma scores 'breakthrough' status

Antibiotic developer scores $50M from biotech billionaire; Biohaven's Alzheimer's drug passes futility test

AstraZeneca, Merck score China OK for Lynparza; Regeneron spotlights mid-stage data for rare disease drug

Japanese biotech pitching iPSC-derived med for the heart gains $26M; Andreessen Horowitz leads $4.1M seed funding for ...

Abbott Laboratories CEO Miles White passes baton down to successor; Lonza CEO Marc Funk hits the exit

Seattle and Daiichi Sankyo at each other's throats; UC Berkeley, UCSF and the University of Washington launch Weill ...

Teva spinout raises $85M in IPO; Novartis beefs up generics unit with $440M deal

Special report: Twenty extraordinary women in biopharma R&D who worked their way to the top

AncestryDNA chief takes on liquid biopsy challenge; Thomas Lynch chairs former colleague's cancer startup

Gilead's ex-investor relations chief takes CFO job at Sangamo; Former GE Healthcare exec takes the helm at Vectura ...

Christopher Haqq joins Elicio to hunt father's RAS cancer; Kronos expands top team with Gilead, Baylor vets